Login Register Cart 0
Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Sex-Specific Association between Antioxidant Defense System and Therapeutic Response to Risperidone in Schizophrenia: A Prospective Longitudinal Study

Author(s): Haixia Liu, Hua Liu, Shuling Jiang, Lei Su, Yi Lu, Zhenli Chen, Xiaojing Li, Xirong Li, Xuemei Wang*, Meihong Xiu* and Xiangyang Zhang*

Volume 20, Issue 9, 2022

Published on: 21 April, 2022

Page: [1793 - 1803] Pages: 11

DOI: 10.2174/1570159X19666211111123918

Price: $65

Abstract

Background: There are various differences in response to different antipsychotics and antioxidant defense systems (ADS) by sex. Previous studies have shown that several ADS enzymes are closely related to the treatment response of patients with antipsychotics-naïve first-episode (ANFE) schizophrenia.

Objective: Therefore, the main goal of this study was to assess the sex difference in the relationship between changes in ADS enzyme activities and risperidone response.

Methods: The plasma activities of glutathione peroxidase (GPx), catalase (CAT), superoxide dismutase (SOD), and total antioxidant status (TAS) were measured in 218 patients and 125 healthy controls. Patients were treated with risperidone for 3 months, and we measured PANSS for psychopathological symptoms and ADS biomarkers at baseline and at the end of 3 months of treatment. We compared sex-specific group differences between 50 non-responders and 168 responders at baseline and at the end of the three months of treatment.

Results: We found that female patients responded better to risperidone treatment than male patients. At baseline and 3-month follow-up, there were no significant sex differences in TAS levels and three ADS enzyme activities. Interestingly, only in female patients, after 12 weeks of risperidone treatment, the GPx activity of responders was higher than that of non-responders.

Conclusion: These results indicate that after treatment with risperidone, changes in GPx activity were associated with treatment response, suggesting that changes in GPx may be a predictor of response to risperidone treatment in female patients with ANFE schizophrenia.

Keywords: Schizophrenia, sex difference, antioxidants, risperidone, therapeutic response, antipsychotics.

« Previous
Graphical Abstract

[1]
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018, 392(10159), 1789-1858.
[http://dx.doi.org/10.1016/S0140-6736(18)32279-7] [PMID: 30496104]
[2]
Lieberman, J.A.; Stroup, T.S.; McEvoy, J.P.; Swartz, M.S.; Rosenheck, R.A.; Perkins, D.O.; Keefe, R.S.; Davis, S.M.; Davis, C.E.; Lebowitz, B.D.; Severe, J.; Hsiao, J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med., 2005, 353(12), 1209-1223.
[http://dx.doi.org/10.1056/NEJMoa051688] [PMID: 16172203]
[3]
Huhn, M.; Nikolakopoulou, A.; Schneider-Thoma, J.; Krause, M.; Samara, M.; Peter, N.; Arndt, T.; Bäckers, L.; Rothe, P.; Cipriani, A.; Davis, J.; Salanti, G.; Leucht, S. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet, 2019, 394(10202), 939-951.
[http://dx.doi.org/10.1016/S0140-6736(19)31135-3] [PMID: 31303314]
[4]
Peng, S.; Li, W.; Lv, L.; Zhang, Z.; Zhan, X. BDNF as a biomarker in diagnosis and evaluation of treatment for schizophrenia and depression. Discov. Med., 2018, 26(143), 127-136.
[PMID: 30586536]
[5]
Li, X.R.; Xiu, M.H.; Guan, X.N.; Wang, Y.C.; Wang, J.; Leung, E.; Zhang, X.Y. Altered antioxidant defenses in drug-naive first episode patients with schizophrenia are associated with poor treatment response to risperidone: 12-week results from a prospective longitudinal study. Neurotherapeutics, 2021, 18(2), 1316-1324.
[http://dx.doi.org/10.1007/s13311-021-01036-3] [PMID: 33791970]
[6]
Orlovska-Waast, S.; Köhler-Forsberg, O.; Brix, S.W.; Nordentoft, M.; Kondziella, D.; Krogh, J.; Benros, M.E. Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis. Mol. Psychiatry, 2019, 24(6), 869-887.
[http://dx.doi.org/10.1038/s41380-018-0220-4] [PMID: 30116031]
[7]
Hassan, W.; Silva, C.E.; Mohammadzai, I.U.; da Rocha, J.B. J, L.F. Association of oxidative stress to the genesis of anxiety: implications for possible therapeutic interventions. Curr. Neuropharmacol., 2014, 12(2), 120-139.
[http://dx.doi.org/10.2174/1570159X11666131120232135] [PMID: 24669207]
[8]
Madireddy, S.; Madireddy, S. Regulation of reactive oxygen species-mediated damage in the pathogenesis of schizophrenia. Brain Sci., 2020, 10(10), E742.
[http://dx.doi.org/10.3390/brainsci10100742] [PMID: 33081261]
[9]
Nucifora, L.G.; Tanaka, T.; Hayes, L.N.; Kim, M.; Lee, B.J.; Matsuda, T.; Nucifora, F.C., Jr; Sedlak, T.; Mojtabai, R.; Eaton, W.; Sawa, A. Reduction of plasma glutathione in psychosis associated with schizophrenia and bipolar disorder in translational psychiatry. Transl. Psychiatry, 2017, 7(8), e1215.
[http://dx.doi.org/10.1038/tp.2017.178] [PMID: 28892069]
[10]
Yao, J.K.; Reddy, R.; McElhinny, L.G.; van Kammen, D.P. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr. Res., 1998, 32(1), 1-8.
[http://dx.doi.org/10.1016/S0920-9964(98)00030-9] [PMID: 9690328]
[11]
Fraguas, D.; Díaz-Caneja, C.M.; Rodríguez-Quiroga, A.; Arango, C. Oxidative stress and inflammation in early onset first episode psychosis: A systematic review and meta-analysis. Int. J. Neuropsychopharmacol., 2017, 20(6), 435-444.
[http://dx.doi.org/10.1093/ijnp/pyx015] [PMID: 28575316]
[12]
Steullet, P.; Cabungcal, J.H.; Coyle, J.; Didriksen, M.; Gill, K.; Grace, A.A.; Hensch, T.K.; LaMantia, A.S.; Lindemann, L.; Maynard, T.M.; Meyer, U.; Morishita, H.; O’Donnell, P.; Puhl, M.; Cuenod, M.; Do, K.Q. Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia. Mol. Psychiatry, 2017, 22(7), 936-943.
[http://dx.doi.org/10.1038/mp.2017.47] [PMID: 28322275]
[13]
Coughlin, J.M.; Hayes, L.N.; Tanaka, T.; Xiao, M.; Yolken, R.H.; Worley, P.; Leweke, F.M.; Sawa, A. Reduced superoxide dismutase-1 (SOD1) in cerebrospinal fluid of patients with early psychosis in association with clinical features. Schizophr. Res., 2017, 183, 64-69.
[http://dx.doi.org/10.1016/j.schres.2016.10.040] [PMID: 27889384]
[14]
Xiu, M.H.; Li, Z.; Chen, D.C.; Chen, S.; Curbo, M.E.; Wu, H.E.; Tong, Y.S.; Tan, S.P.; Zhang, X.Y. Interrelationships between BDNF, superoxide dismutase, and cognitive impairment in drug-naive first-episode patients with schizophrenia. Schizophr. Bull., 2020, 46(6), 1498-1510.
[http://dx.doi.org/10.1093/schbul/sbaa062] [PMID: 32390043]
[15]
Fraguas, D.; Díaz-Caneja, C.M.; Ayora, M.; Hernández-Álvarez, F.; Rodríguez-Quiroga, A.; Recio, S.; Leza, J.C.; Arango, C. Oxidative stress and inflammation in first-episode psychosis: A systematic review and meta-analysis. Schizophr. Bull., 2019, 45(4), 742-751.
[http://dx.doi.org/10.1093/schbul/sby125] [PMID: 30169868]
[16]
Tsugawa, S.; Noda, Y.; Tarumi, R.; Mimura, Y.; Yoshida, K.; Iwata, Y.; Elsalhy, M.; Kuromiya, M.; Kurose, S.; Masuda, F.; Morita, S.; Ogyu, K.; Plitman, E.; Wada, M.; Miyazaki, T.; Graff-Guerrero, A.; Mimura, M.; Nakajima, S. Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis. J. Psychopharmacol., 2019, 33(10), 1199-1214.
[http://dx.doi.org/10.1177/0269881119845820] [PMID: 31039654]
[17]
Flatow, J.; Buckley, P.; Miller, B.J. Meta-analysis of oxidative stress in schizophrenia. Biol. Psychiatry, 2013, 74(6), 400-409.
[http://dx.doi.org/10.1016/j.biopsych.2013.03.018] [PMID: 23683390]
[18]
Tang, W.; Wang, Y.; Xu, F.; Fan, W.; Zhang, Y.; Fan, K.; Wang, W.; Zhang, Y.; Zhang, C. Omega-3 fatty acids ameliorate cognitive dysfunction in schizophrenia patients with metabolic syndrome. Brain Behav. Immun., 2020, 88, 529-534.
[http://dx.doi.org/10.1016/j.bbi.2020.04.034] [PMID: 32304881]
[19]
Firth, J.; Stubbs, B.; Sarris, J.; Rosenbaum, S.; Teasdale, S.; Berk, M.; Yung, A.R. The effects of vitamin and mineral supplementation on symptoms of schizophrenia: a systematic review and meta-analysis - CORRIGENDUM. Psychol. Med., 2018, 48(3), 528.
[http://dx.doi.org/10.1017/S0033291717001866] [PMID: 28712367]
[20]
Pawełczyk, T.; Grancow-Grabka, M.; Trafalska, E.; Szemraj, J.; Pawełczyk, A. Oxidative stress reduction related to the efficacy of n-3 polyunsaturated fatty acids in first episode schizophrenia: Secondary outcome analysis of the OFFER randomized trial. Prostaglandins Leukot. Essent. Fatty Acids, 2017, 121, 7-13.
[http://dx.doi.org/10.1016/j.plefa.2017.05.004] [PMID: 28651701]
[21]
Minarini, A.; Ferrari, S.; Galletti, M.; Giambalvo, N.; Perrone, D.; Rioli, G.; Galeazzi, G.M. N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects. Expert Opin. Drug Metab. Toxicol., 2017, 13(3), 279-292.
[http://dx.doi.org/10.1080/17425255.2017.1251580] [PMID: 27766914]
[22]
Conus, P.; Seidman, L.J.; Fournier, M.; Xin, L.; Cleusix, M.; Baumann, P.S.; Ferrari, C.; Cousins, A.; Alameda, L.; Gholam-Rezaee, M.; Golay, P.; Jenni, R.; Woo, T.W.; Keshavan, M.S.; Eap, C.B.; Wojcik, J.; Cuenod, M.; Buclin, T.; Gruetter, R.; Do, K.Q. N-acetylcysteine in a double-blind randomized placebo-controlled trial: Toward biomarker-guided treatment in early psychosis. Schizophr. Bull., 2018, 44(2), 317-327.
[http://dx.doi.org/10.1093/schbul/sbx093] [PMID: 29462456]
[23]
Zhang, X.Y.; Zhou, D.F.; Shen, Y.C.; Zhang, P.Y.; Zhang, W.F.; Liang, J.; Chen, D.C.; Xiu, M.H.; Kosten, T.A.; Kosten, T.R. Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia. Neuropharmacology, 2012, 62(5-6), 1928-1934.
[http://dx.doi.org/10.1016/j.neuropharm.2011.12.014] [PMID: 22227558]
[24]
Schotte, A.; Janssen, P.F.; Gommeren, W.; Luyten, W.H.; Van Gompel, P.; Lesage, A.S.; De Loore, K.; Leysen, J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl.), 1996, 124(1-2), 57-73.
[http://dx.doi.org/10.1007/BF02245606] [PMID: 8935801]
[25]
Dakhale, G.; Khanzode, S.; Khanzode, S.; Saoji, A.; Khobragade, L.; Turankar, A. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology, 2004, 49(4), 205-209.
[http://dx.doi.org/10.1159/000077368] [PMID: 15154399]
[26]
Wei, Z.; Bai, O.; Richardson, J.S.; Mousseau, D.D.; Li, X.M. Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. J. Neurosci. Res., 2003, 73(3), 364-368.
[http://dx.doi.org/10.1002/jnr.10668] [PMID: 12868070]
[27]
Yao, J.K.; Reddy, R.; McElhinny, L.G.; van Kammen, D.P. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J. Psychiatr. Res., 1998, 32(6), 385-391.
[http://dx.doi.org/10.1016/S0022-3956(98)00028-4] [PMID: 9844955]
[28]
Raffa, M.; Mechri, A.; Othman, L.B.; Fendri, C.; Gaha, L.; Kerkeni, A. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33(7), 1178-1183.
[http://dx.doi.org/10.1016/j.pnpbp.2009.06.018] [PMID: 19576938]
[29]
Lepping, P.; Sambhi, R.S.; Whittington, R.; Lane, S.; Poole, R. Clinical relevance of findings in trials of antipsychotics: systematic review. Br. J. Psychiatry, 2011, 198(5), 341-345.
[http://dx.doi.org/10.1192/bjp.bp.109.075366] [PMID: 21525517]
[30]
Tendilla-Beltrán, H.; Meneses-Prado, S.; Vázquez-Roque, R.A.; Tapia-Rodríguez, M.; Vázquez-Hernández, A.J.; Coatl-Cuaya, H.; Martín-Hernández, D.; MacDowell, K.S.; Garcés-Ramírez, L.; Leza, J.C.; Flores, G. Risperidone ameliorates prefrontal cortex neural atrophy and oxidative/nitrosative stress in brain and peripheral blood of rats with neonatal ventral hippocampus lesion. J. Neurosci., 2019, 39(43), 8584-8599.
[http://dx.doi.org/10.1523/JNEUROSCI.1249-19.2019] [PMID: 31519825]
[31]
Casquero-Veiga, M.; García-García, D.; MacDowell, K.S.; Pérez-Caballero, L.; Torres-Sánchez, S.; Fraguas, D.; Berrocoso, E.; Leza, J.C.; Arango, C.; Desco, M.; Soto-Montenegro, M.L. Risperidone administered during adolescence induced metabolic, anatomical and inflammatory/oxidative changes in adult brain: A PET and MRI study in the maternal immune stimulation animal model. Eur. Neuropsychopharmacol., 2019, 29(7), 880-896.
[http://dx.doi.org/10.1016/j.euroneuro.2019.05.002] [PMID: 31229322]
[32]
Zhang, X.Y.; Tan, Y.L.; Cao, L.Y.; Wu, G.Y.; Xu, Q.; Shen, Y.; Zhou, D.F. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr. Res., 2006, 81(2-3), 291-300.
[http://dx.doi.org/10.1016/j.schres.2005.10.011] [PMID: 16309894]
[33]
Dietrich-Muszalska, A.; Kolodziejczyk-Czepas, J.; Nowak, P. Comparative study of the effects of atypical antipsychotic drugs on plasma and urine biomarkers of oxidative stress in schizophrenic patients. Neuropsychiatr. Dis. Treat., 2021, 17, 555-565.
[http://dx.doi.org/10.2147/NDT.S283395] [PMID: 33628026]
[34]
Padurariu, M.; Ciobica, A.; Dobrin, I.; Stefanescu, C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci. Lett., 2010, 479(3), 317-320.
[http://dx.doi.org/10.1016/j.neulet.2010.05.088] [PMID: 20561936]
[35]
Liu, H.; Yu, R.; Gao, Y.; Li, X.; Guan, X.; Thomas, K.; Xiu, M.; Zhang, X. Antioxidant enzymes and weight gain in drug-naive first episode schizophrenia patients treated with risperidone for 12 weeks: a prospective longitudinal study. Curr. Neuropharmacol., 2021. [Epub ahead of print
[36]
Hendouei, N.; Farnia, S.; Mohseni, F.; Salehi, A.; Bagheri, M.; Shadfar, F.; Barzegar, F.; Hoseini, S.D.; Charati, J.Y.; Shaki, F. Alterations in oxidative stress markers and its correlation with clinical findings in schizophrenic patients consuming perphenazine, clozapine and risperidone. Biomed. Pharmacother., 2018, 103, 965-972.
[http://dx.doi.org/10.1016/j.biopha.2018.04.109] [PMID: 29710513]
[37]
Dietrich-Muszalska, A.; Kolińska-Łukaszuk, J. Comparative effects of aripiprazole and selected antipsychotic drugs on lipid peroxidation in plasma. Psychiatry Clin. Neurosci., 2018, 72(5), 329-336.
[http://dx.doi.org/10.1111/pcn.12631] [PMID: 29280533]
[38]
Messias, E.L.; Chen, C.Y.; Eaton, W.W. Epidemiology of schizophrenia: review of findings and myths. Psychiatr. Clin. North Am., 2007, 30(3), 323-338.
[http://dx.doi.org/10.1016/j.psc.2007.04.007] [PMID: 17720026]
[39]
Abel, K.M.; Drake, R.; Goldstein, J.M. Sex differences in schizophrenia. Int. Rev. Psychiatry, 2010, 22(5), 417-428.
[http://dx.doi.org/10.3109/09540261.2010.515205] [PMID: 21047156]
[40]
Ceskova, E.; Prikryl, R.; Libiger, J.; Svancara, J.; Jarkovsky, J. Gender differences in the treatment of first-episode schizophrenia: Results from the European First Episode Schizophrenia Trial. Schizophr. Res., 2015, 169(1-3), 303-307.
[http://dx.doi.org/10.1016/j.schres.2015.10.013] [PMID: 26545298]
[41]
Thorup, A.; Albert, N.; Bertelsen, M.; Petersen, L.; Jeppesen, P.; Le Quack, P.; Krarup, G.; Jørgensen, P.; Nordentoft, M. Gender differences in first-episode psychosis at 5-year follow-up--two different courses of disease? Results from the OPUS study at 5-year follow-up. Eur. Psychiatry, 2014, 29(1), 44-51.
[http://dx.doi.org/10.1016/j.eurpsy.2012.11.005] [PMID: 23394824]
[42]
Lange, B.; Mueller, J.K.; Leweke, F.M.; Bumb, J.M. How gender affects the pharmacotherapeutic approach to treating psychosis - a systematic review. Expert Opin. Pharmacother., 2017, 18(4), 351-362.
[http://dx.doi.org/10.1080/14656566.2017.1288722] [PMID: 28129701]
[43]
Szymanski, S.; Lieberman, J.A.; Alvir, J.M.; Mayerhoff, D.; Loebel, A.; Geisler, S.; Chakos, M.; Koreen, A.; Jody, D.; Kane, J. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am. J. Psychiatry, 1995, 152(5), 698-703.
[http://dx.doi.org/10.1176/ajp.152.5.698] [PMID: 7726309]
[44]
Cotton, S.M.; Lambert, M.; Schimmelmann, B.G.; Foley, D.L.; Morley, K.I.; McGorry, P.D.; Conus, P. Gender differences in premorbid, entry, treatment, and outcome characteristics in a treated epidemiological sample of 661 patients with first episode psychosis. Schizophr. Res., 2009, 114(1-3), 17-24.
[http://dx.doi.org/10.1016/j.schres.2009.07.002] [PMID: 19635660]
[45]
Heck, A.L.; Handa, R.J. Sex differences in the hypothalamic-pituitary-adrenal axis’ response to stress: an important role for gonadal hormones. Neuropsychopharmacology, 2019, 44(1), 45-58.
[http://dx.doi.org/10.1038/s41386-018-0167-9] [PMID: 30111811]
[46]
Brzezinski, A.; Brzezinski-Sinai, N.A.; Seeman, M.V. Treating schizophrenia during menopause. Menopause, 2017, 24(5), 582-588.
[http://dx.doi.org/10.1097/GME.0000000000000772] [PMID: 27824682]
[47]
Mendrek, A.; Stip, E. Sexual dimorphism in schizophrenia: is there a need for gender-based protocols? Expert Rev. Neurother., 2011, 11(7), 951-959.
[http://dx.doi.org/10.1586/ern.11.78] [PMID: 21721913]
[48]
Jukic, M.M.; Smith, R.L.; Haslemo, T.; Molden, E.; Ingelman-Sundberg, M. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. Lancet Psychiatry, 2019, 6(5), 418-426.
[http://dx.doi.org/10.1016/S2215-0366(19)30088-4] [PMID: 31000417]
[49]
Kay, S.R.; Fiszbein, A.; Opler, L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull., 1987, 13(2), 261-276.
[http://dx.doi.org/10.1093/schbul/13.2.261] [PMID: 3616518]
[50]
Cao, B.; Cho, R.Y.; Chen, D.; Xiu, M.; Wang, L.; Soares, J.C.; Zhang, X.Y. Treatment response prediction and individualized identification of first-episode drug-naive schizophrenia using brain functional connectivity. Mol. Psychiatry, 2020, 25, 906-913.
[PMID: 29921920]
[51]
Chen, Y.L.; Chen, K.P.; Chiu, C.C.; Tai, M.H.; Lung, F.W. Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics. BMC Psychiatry, 2018, 18(1), 376.
[http://dx.doi.org/10.1186/s12888-018-1950-1] [PMID: 30509308]
[52]
Usall, J.; Suarez, D.; Haro, J.M. Gender differences in response to antipsychotic treatment in outpatients with schizophrenia. Psychiatry Res., 2007, 153(3), 225-231.
[http://dx.doi.org/10.1016/j.psychres.2006.09.016] [PMID: 17681611]
[53]
Cechnicki, A.; Bielańska, A.; Mętel, D.; Susz, K.; Błądziński, P.; Plencler-Bańczyk, I.; Kalisz, A. Comparison of the long-term treatment outcomes of women and men diagnosed with schizophrenia over a period of 20 years. A prospective study. Compr. Psychiatry, 2018, 84, 62-67.
[http://dx.doi.org/10.1016/j.comppsych.2018.03.011] [PMID: 29694934]
[54]
Ran, M.S.; Mao, W.J.; Chan, C.L.; Chen, E.Y.; Conwell, Y. Gender differences in outcomes in people with schizophrenia in rural China: 14-year follow-up study. Br. J. Psychiatry, 2015, 206(4), 283-288.
[http://dx.doi.org/10.1192/bjp.bp.113.139733] [PMID: 25573398]
[55]
Goldstein, J.M.; Cohen, L.S.; Horton, N.J.; Lee, H.; Andersen, S.; Tohen, M.; Crawford, A.; Tollefson, G. Sex differences in clinical response to olanzapine compared with haloperidol. Psychiatry Res., 2002, 110(1), 27-37.
[http://dx.doi.org/10.1016/S0165-1781(02)00028-8] [PMID: 12007591]
[56]
Wu, J.Q.; Kosten, T.R.; Zhang, X.Y. Free radicals, antioxidant defense systems, and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2013, 46, 200-206.
[http://dx.doi.org/10.1016/j.pnpbp.2013.02.015] [PMID: 23470289]
[57]
Smith, S. Gender differences in antipsychotic prescribing. Int. Rev. Psychiatry, 2010, 22(5), 472-484.
[http://dx.doi.org/10.3109/09540261.2010.515965] [PMID: 21047160]
[58]
Soldin, O.P.; Chung, S.H.; Mattison, D.R. Sex differences in drug disposition. J. Biomed. Biotechnol., 2011, 2011, 187103.
[http://dx.doi.org/10.1155/2011/187103] [PMID: 21403873]
[59]
Schwartz, J.B. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin. Pharmacol. Ther., 2007, 82(1), 87-96.
[http://dx.doi.org/10.1038/sj.clpt.6100226] [PMID: 17495875]
[60]
Bebawy, M.; Chetty, M. Gender differences in p-glycoprotein expression and function: effects on drug disposition and outcome. Curr. Drug Metab., 2009, 10(4), 322-328.
[http://dx.doi.org/10.2174/138920009788498996] [PMID: 19519340]
[61]
Zang, H.; Carlström, K.; Arner, P.; Hirschberg, A.L. Effects of treatment with testosterone alone or in combination with estrogen on insulin sensitivity in postmenopausal women. Fertil. Steril., 2006, 86(1), 136-144.
[http://dx.doi.org/10.1016/j.fertnstert.2005.12.039] [PMID: 16750207]
[62]
Qu, M.; Wang, J.; Chen, D.C.; Chen, S.; Xiu, M.H.; Zhang, X.Y. Sex-specific association between peripheral superoxide dismutase, BDNF and cognitive impairment in drug-naive first episode patients with schizophrenia. Free Radic. Biol. Med., 2020, 160, 887-893.
[http://dx.doi.org/10.1016/j.freeradbiomed.2020.09.014] [PMID: 32949664]
[63]
Dadheech, G.; Mishra, S.; Gautam, S.; Sharma, P. Evaluation of antioxidant deficit in schizophrenia. Indian J. Psychiatry, 2008, 50(1), 16-20.
[http://dx.doi.org/10.4103/0019-5545.39753] [PMID: 19771301]
[64]
Jordan, W.; Dobrowolny, H.; Bahn, S.; Bernstein, H.G.; Brigadski, T.; Frodl, T.; Isermann, B.; Lessmann, V.; Pilz, J.; Rodenbeck, A.; Schiltz, K.; Schwedhelm, E.; Tumani, H.; Wiltfang, J.; Guest, P.C.; Steiner, J. Oxidative stress in drug-naïve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders. Eur. Arch. Psychiatry Clin. Neurosci., 2018, 268(2), 129-143.
[http://dx.doi.org/10.1007/s00406-016-0749-7] [PMID: 27913877]
[65]
Monte, A.S.; da Silva, F.E.R.; Lima, C.N.C.; Vasconcelos, G.S.; Gomes, N.S.; Miyajima, F.; Vasconcelos, S.M.M.; Gama, C.S.; Seeman, M.V.; de Lucena, D.F.; Macedo, D.S. Sex influences in the preventive effects of N-acetylcysteine in a two-hit animal model of schizophrenia. J. Psychopharmacol., 2020, 34(1), 125-136.
[http://dx.doi.org/10.1177/0269881119875979] [PMID: 31556775]
[66]
Monte, A.S.; Mello, B.S.F.; Borella, V.C.M.; da Silva Araujo, T.; da Silva, F.E.R.; Sousa, F.C.F.; de Oliveira, A.C.P.; Gama, C.S.; Seeman, M.V.; Vasconcelos, S.M.M.; Lucena, D.F.; Macêdo, D. Two-hit model of schizophrenia induced by neonatal immune activation and peripubertal stress in rats: Study of sex differences and brain oxidative alterations. Behav. Brain Res., 2017, 331, 30-37.
[http://dx.doi.org/10.1016/j.bbr.2017.04.057] [PMID: 28527693]
[67]
Kander, M.C.; Cui, Y.; Liu, Z. Gender difference in oxidative stress: a new look at the mechanisms for cardiovascular diseases. J. Cell. Mol. Med., 2017, 21(5), 1024-1032.
[http://dx.doi.org/10.1111/jcmm.13038] [PMID: 27957792]
[68]
Lane, H.Y.; Chang, Y.C.; Chiu, C.C.; Chen, M.L.; Hsieh, M.H.; Chang, W.H. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am. J. Psychiatry, 2002, 159(9), 1593-1595.
[http://dx.doi.org/10.1176/appi.ajp.159.9.1593] [PMID: 12202283]
[69]
Lv, Q.; Guo, Y.; Zhu, M.; Geng, R.; Cheng, X.; Bao, C.; Wang, Y.; Huang, X.; Zhang, C.; Hao, Y.; Li, Z.; Yi, Z. Predicting individual responses to lithium with oxidative stress markers in drug-free bipolar disorder. World J. Biol. Psychiatry, 2019, 20(10), 778-789.
[http://dx.doi.org/10.1080/15622975.2019.1663929] [PMID: 31595816]
[70]
Andreazza, A.C.; Kauer-Sant’anna, M.; Frey, B.N.; Bond, D.J.; Kapczinski, F.; Young, L.T.; Yatham, L.N. Oxidative stress markers in bipolar disorder: a meta-analysis. J. Affect. Disord., 2008, 111(2-3), 135-144.
[http://dx.doi.org/10.1016/j.jad.2008.04.013] [PMID: 18539338]
[71]
Tunçel, O.K.; Sarısoy, G.; Bilgici, B.; Pazvantoglu, O.; Çetin, E.; Ünverdi, E.; Avcı, B.; Böke, Ö. Oxidative stress in bipolar and schizophrenia patients. Psychiatry Res., 2015, 228(3), 688-694.
[http://dx.doi.org/10.1016/j.psychres.2015.04.046] [PMID: 26117246]
[72]
Saso, L.; Firuzi, O. Pharmacological applications of antioxidants: lights and shadows. Curr. Drug Targets, 2014, 15(13), 1177-1199.
[http://dx.doi.org/10.2174/1389450115666141024113925] [PMID: 25341421]
[73]
Perkins, D.O.; Jeffries, C.D.; Do, K.Q. Potential roles of redox dysregulation in the development of schizophrenia. Biol. Psychiatry, 2020, 88(4), 326-336.
[http://dx.doi.org/10.1016/j.biopsych.2020.03.016] [PMID: 32560962]
[74]
Miljević, C.D.; Nikolić-Kokić, A.; Blagojević, D.; Milovanović, M.; Munjiza, A.; Jukić, M.M.; Pešić, V.; Lečić-Toševski, D.; Spasić, M.B. Association between neurological soft signs and antioxidant enzyme activity in schizophrenic patients. Psychiatry Res., 2018, 269, 746-752.
[http://dx.doi.org/10.1016/j.psychres.2018.09.009] [PMID: 30273900]
[75]
Shao, X.; Yan, C.; Sun, D.; Fu, C.; Tian, C.; Duan, L.; Zhu, G. Association between glutathione peroxidase-1 (GPx-1) polymorphisms and schizophrenia in the Chinese han population. Neuropsychiatr. Dis. Treat., 2020, 16, 2297-2305.
[http://dx.doi.org/10.2147/NDT.S272278] [PMID: 33116528]
[76]
Buckman, T.D.; Kling, A.; Sutphin, M.S.; Steinberg, A.; Eiduson, S. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables. Psychiatry Res., 1990, 31(1), 1-14.
[http://dx.doi.org/10.1016/0165-1781(90)90103-C] [PMID: 1969170]
[77]
Stojković, T.; Radonjić, N.V.; Velimirović, M.; Jevtić, G.; Popović, V.; Doknić, M.; Petronijević, N.D. Risperidone reverses phencyclidine induced decrease in glutathione levels and alterations of antioxidant defense in rat brain. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2012, 39(1), 192-199.
[http://dx.doi.org/10.1016/j.pnpbp.2012.06.013] [PMID: 22735395]
[78]
Dempster, K.; Jeon, P.; MacKinley, M.; Williamson, P.; Théberge, J.; Palaniyappan, L. Early treatment response in first episode psychosis: a 7-T magnetic resonance spectroscopic study of glutathione and glutamate. Mol. Psychiatry, 2020, 25(8), 1640-1650.
[http://dx.doi.org/10.1038/s41380-020-0704-x] [PMID: 32205866]
[79]
Limongi, R.; Jeon, P.; Théberge, J.; Palaniyappan, L. Counteracting effects of glutathione on the glutamate-driven excitation/inhibition imbalance in first-episode schizophrenia: A 7T MRS and dynamic causal modeling study. Antioxidants, 2021, 10(1), 75.
[http://dx.doi.org/10.3390/antiox10010075] [PMID: 33430154]
[80]
Ruiz-Litago, F.; Seco, J.; Echevarría, E.; Martínez-Cengotitabengoa, M.; Gil, J.; Irazusta, J.; González-Pinto, A.M. Adaptive response in the antioxidant defence system in the course and outcome in first-episode schizophrenia patients: a 12-months follow-up study. Psychiatry Res., 2012, 200(2-3), 218-222.
[http://dx.doi.org/10.1016/j.psychres.2012.07.024] [PMID: 22884309]
[81]
Bayir, H.; Marion, D.W.; Puccio, A.M.; Wisniewski, S.R.; Janesko, K.L.; Clark, R.S.; Kochanek, P.M. Marked gender effect on lipid peroxidation after severe traumatic brain injury in adult patients. J. Neurotrauma, 2004, 21(1), 1-8.
[http://dx.doi.org/10.1089/089771504772695896] [PMID: 14987460]
[82]
Brunelli, E.; Domanico, F.; La Russa, D.; Pellegrino, D. Sex differences in oxidative stress biomarkers. Curr. Drug Targets, 2014, 15(8), 811-815.
[http://dx.doi.org/10.2174/1389450115666140624112317] [PMID: 24958098]
[83]
Sumner, B.E.; Fink, G. Effects of acute estradiol on 5-hydroxytryptamine and dopamine receptor subtype mRNA expression in female rat brain. Mol. Cell. Neurosci., 1993, 4(1), 83-92.
[http://dx.doi.org/10.1006/mcne.1993.1010] [PMID: 19912911]
[84]
Fink, G.; Sumner, B.E.; McQueen, J.K.; Wilson, H.; Rosie, R. Sex steroid control of mood, mental state and memory. Clin. Exp. Pharmacol. Physiol., 1998, 25(10), 764-775.
[http://dx.doi.org/10.1111/j.1440-1681.1998.tb02151.x] [PMID: 9784914]
[85]
Sánchez, M.G.; Bourque, M.; Morissette, M.; Di Paolo, T. Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther., 2010, 16(3), e43-e71.
[http://dx.doi.org/10.1111/j.1755-5949.2010.00163.x] [PMID: 20557567]
[86]
Dluzen, D.E. Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system. J. Neurocytol., 2000, 29(5-6), 387-399.
[http://dx.doi.org/10.1023/A:1007117424491] [PMID: 11424955]
[87]
Diwakar, L.; Kenchappa, R.S.; Annepu, J.; Saeed, U.; Sujanitha, R.; Ravindranath, V. Down-regulation of glutaredoxin by estrogen receptor antagonist renders female mice susceptible to excitatory amino acid mediated complex I inhibition in CNS. Brain Res., 2006, 1125(1), 176-184.
[http://dx.doi.org/10.1016/j.brainres.2006.10.015] [PMID: 17109834]
[88]
Alkayed, N.J.; Harukuni, I.; Kimes, A.S.; London, E.D.; Traystman, R.J.; Hurn, P.D. Gender-linked brain injury in experimental stroke. Stroke, 1998, 29(1), 159-165.
[http://dx.doi.org/10.1161/01.STR.29.1.159] [PMID: 9445346]

Rights & Permissions Print Cite
Article Metrics
24
1
© 2024 Bentham Science Publishers | Privacy Policy